Kosmidis, Michalis L. et al "Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis." Neurology - Neuroimmunology Neuroinflammation 6.4 (2019): e581. Web. 18 Feb. 2020.